Ofirmev and Weakness - a phase IV clinical study of FDA data

Summary:

Weakness is reported as a side effect among people who take Ofirmev (acetaminophen), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Folic Acid, and have Lung cancer - non-small cell.

The phase IV clinical study analyzes which people have Weakness when taking Ofirmev. It is created by eHealthMe based on reports of 817 people who have side effects when taking Ofirmev from the FDA, and is updated regularly.

What is Ofirmev?

Ofirmev has active ingredients of acetaminophen. eHealthMe is studying from 817 Ofirmev users. Check the latest studies of Ofirmev.

What is Weakness?

Weakness is found to be associated with 3,641 drugs and 6,611 conditions by eHealthMe. Check the latest studies of Weakness.

On Jul, 09, 2026

817 people reported to have side effects when taking Ofirmev.
Among them, 26 people (3.18%) have Weakness.

Among these 26 people:

How long have people been on Ofirmev when they have Weakness? *

What is the gender of people who have Weakness when taking Ofirmev? *

female: 20 %
male: 80 %

What is the age of people who have Weakness when taking Ofirmev? *

What are other drugs people take besides Ofirmev? *

Eliquis: 17 people, 65.38%
Folic Acid: 17 people, 65.38%
Zometa: 16 people, 61.54%
Torsemide: 16 people, 61.54%
Calcium: 16 people, 61.54%
Tabrecta: 16 people, 61.54%
Acetaminophen: 14 people, 53.85%
Hydromorphone Hydrochloride: 4 people, 15.38%
Zofran: 3 people, 11.54%
Pantoprazole: 3 people, 11.54%

What are other side effects people have besides Weakness? *

Dizziness: 20 people, 76.92%
Fatigue (feeling of tiredness): 19 people, 73.08%
Fluid Retention (an abnormal accumulation of fluid in the blood): 18 people, 69.23%
Hypoacusis (loss of hearing): 17 people, 65.38%
Dyspnea (difficult or laboured breathing): 17 people, 65.38%
Weight Increased: 16 people, 61.54%
Lymphoedema (localized fluid retention and tissue swelling): 16 people, 61.54%
Oedema Peripheral (superficial swelling): 16 people, 61.54%
Pleural Effusion (water on the lungs): 16 people, 61.54%
Hyperkalemia (damage to or disease of the kidney): 16 people, 61.54%

What are the existing conditions these people have? *

Back Pain: 16 people, 61.54%
Lung Cancer - Non-Small Cell (lung cancer): 16 people, 61.54%
Venous Thrombosis Limb (blood clot that forms in a vein in the limb): 7 people, 26.92%
Thrombosis (formation of a blood clot inside a blood vessel): 6 people, 23.08%
Pain: 3 people, 11.54%
Infusion Related Reaction: 2 people, 7.69%
Relapsing-Remitting Multiple Sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 2 people, 7.69%
Heart Transplant Rejection: 1 person, 3.85%
Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 1 person, 3.85%
Chickenpox (infection with varicella zoster virus): 1 person, 3.85%

* Approximation only. Some reports may have incomplete information.

Do you take Ofirmev and have Weakness?

- Check whether Weakness is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Ofirmev:

Ofirmev (817 reports)

Weakness treatments and more:

Weakness (586,876 reports)

Browse all side effects of Ofirmev:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Weakness:

Weakness (3,641 drugs)

Browse all the conditions that are associated with Weakness:

Weakness (6,611 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on acetaminophen (the active ingredients of Ofirmev) and Ofirmev (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.